Ireland
--:--IST
Recruiting Not applicable

Proof of Concept, Randomized, and Crossover Study, to Assess the Effectiveness of Two Types of Compression Garments in Lipedema

NCT06964828 · tracked via the Priya Life Science Spain tracker
Sponsor
Isabel Forner-Cordero, MD, PhD
Phase
Not applicable
Started
2024-05-08
Last updated
2025-05-14

Condition(s) studied

Lipedema

Investigational drug(s) / intervention(s)

Flat-knitted compression garment

Flat-knitted compression garment: Flat knitted compression garments

Study summary

The goal of this prospective randomized crossover experimental study is to assess the effectiveness and tolerance of circular and flat fabric garments in stabilizing lower-limb volume in lipedema. It will assess the effectiveness of the garments and determine any differences between both types of hosiery currently used in routine clinical practice. Participants will be prescribed either circular or flat-knitted pantyhose and wear them daily for 6 months. After 6 months, they will change the type of garment.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of lipedema: increased lowe-limb volume, disproportion between upper and lower body, and pain. * Lipedema type III stages 1 or 2. * Negative pitting sign. * In maintenance treatment phase with a class II circular-knitted compression garment for at least 6 months. * Adequate compliance with compression garments (worn during the day, except during personal hygiene and water-related activities). * Written informed consent to participate. Exclusion Criteria: * Lipedema with fatty lobulations. * Body Mass Index (BMI) ≥ 30 kg/m2. * Waist-to-Height Ratio \> 0.53. * Pregnancy. * Renal, hepatic, or cardiac insufficiency. * Thrombosis in the lower extremities. * Infection in the lower extremities. * Active oncological process. * Current treatment with corticosteroids and other medications that promote fluid retention. * Inability to read the Patient Information Form (HIP) and/or provide consent to participate in the study.

Primary outcome measure(s)

  • Percentage of Volume Change (PVC) — at the 6th and 12th month of treatment
    The Percentage of Volume Change (PVC) at the 6th and 12th month of treatment is calculated using the following mathematical formula: PVC = \[ (Baseline volume- final volume)/ baseline volume\] x 100 Where: * Baseline is the reference volume at the beginning of the treatment. * Final Volume is the volume at the end of the treatment period (either at the 6th or 12th month). This calculation provides the percentage change in volume of the lower limbs over the course of the treatment period compared to the initial volume. We consider maintenance treatment is successful when the Percentage of Volume Change (PVC) is \<10% after 6 or 12 months of treatment, relative to the study's baseline. We define disease progression when the PVC is \>10% at 6 or 12 months, relative to the study's baseline.

Trial sites (1)

FacilityCityRegionStatus
Hospital Universitari i Politecnic La Fe Valencia Valencia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06964828 on ClinicalTrials.gov ↗ ← All trials in Spain